Search Results

Less than ~15% of higher plant species, <5% of bacterial and fungal species, and only a fraction of marine This was more than trial-and-error. It was early structure-based pharmacology. Dr. expands drug matter beyond the familiar and encourages deliberate exploration of chemical novelty, rather than

unique ability to combine storytelling, real-world experience, and scientific clarity makes this more than

article GPCR Publication Highlights βCGRP breaks the mold: Distinct signaling patterns reveal it’s more than

.” — Tom Sakmar This makes them more than biomarkers — they’re potential drivers of disease .

For biotech founders, this is more than a presentation problem. It’s a strategic vulnerability. academic interest to practical significance. 3️⃣ Why it’s different ✅ Differentiation must be more than who you’re building for, why now is the right time, and how your solution fits into something bigger than

science well, but not the value capture From an investor's perspective, this creates confusion rather than 👉 IP discussions happen earlier in fundraising conversations 👉 Investors look for alignment rather than Biotech fundraising will favor teams that use intellectual property as a tool for clarity rather than

Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. start planning around delays BD and investor messaging drifts Timelines become aspirational rather than

Recent studies showed that some AVPR2 mutations could cause biased Gαq/11 protein coupling rather than R68W showed bias to coupling with Gαq/11 protein rather than V162A and wild-type receptor.

Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently than Translate potency and efficacy realistically  → Recognize when deviations reflect biology rather than

By visualizing enzymes as dynamic molecular partners rather than static filters, drug discovery scientists Cytochrome P450: Friend, Foe, and FDA Focus No enzyme class is more important—or more unpredictable—than Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design

GPCR is much more than a podcast? Come check out the brand new Dr.

The suppressive rather than activating effects of pGRP were confined to blood flow at a high shear rate Blockage of PTK2 or interference of CIB1 no more than slightly affected thrombus formation at a low shear

The science evolves, assumptions break, and timelines shift quietly rather than dramatically. The discovery phase stretches longer than planned. The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but

Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

More than a technical overview, this is a story of curiosity, persistence, and using science to meet Rather than being discouraged by challenges, he views them as forcing functions for creativity and growth

This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now!

The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility

GPCR Podcast, we have none other than Dr. Marta Filizola!

Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.

Here, the Schild plot becomes a diagnostic tool  rather than a checkbox test: Slopes >1  often mean incomplete to Partial Agonists Partial agonists complicate things—they activate receptors but less effectively than

Our first guest speaker is none other than Dr. Ben Myers!

determine partner preference; or (iii) the dynamics of GPCR binding to different types of partners rather than

Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous

in academia or biotech, the future belongs to research groups that can orchestrate ecosystems rather than He treats modeling as part of a continuum rather than a separate discipline.

One potential solution is to develop analgesics that act at targets other than opioid receptors.

Hassard is a commercial leader with more than three decades of experience leading sales and marketing

A much smaller conformational change of helix VI upon activation than previously solved class A GPCR-Gi

Unlocking the Secrets of Orthosteric Binding Understanding why some drugs bind better than others is

This is more than review, it’s readiness.

In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have